ASTRAZENECA overnight
announced an agreement for
the acquisition of a 55% stake
in Netherlands-founded biotech
Acerta Pharma.
The US$4 billion deal includes
an upfront payment $2.5 billion
and a further $1.5 billion when
the company’s cancer drug
acalabrutinib is approved in the US.
There is also an option for AZ
to purchase the remaining 45%
of Acerta for US$3 billion, with
AstraZeneca ceo Pascal Soriot
saying the deal is “consistent with
our focus on long term growth and
reflects the role targeted business
development plays in our business
model”.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jan 16
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.